ReviewTherapeutics and clinical risk management2015
Alemtuzumab for the treatment of multiple sclerosis.
Review in Therapeutics and clinical risk management, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.Clinical and experimental immunology · 2018Trial
- 'Immune reset plus': the case for combining immunotherapies to maintain self-tolerance in autoimmune diseases.Frontiers in immunology · 2025Article
- Alemtuzumab treatment for multiple sclerosis in Austria: An observational long-term outcome study.Annals of clinical and translational neurology · 2024Observational
- Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature.Nature reviews. Neurology · 2020Review
- Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus.Acta neurologica Belgica · 2018Article
- Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.Acta neurologica Belgica · 2018Article
- Alemtuzumab for Multiple Sclerosis.Current neurology and neuroscience reports · 2016Review
- Article
- Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Review
- Multiple sclerosis--new treatment modalities.The Indian journal of medical research · 2015Review
- Researchers Expand Focus on Progressive Forms Of Multiple Sclerosis: Efforts to Pinpoint the Beginning of Disease May Yield Clues to Treatment.P & T : a peer-reviewed journal for formulary management · 2015Article
- Intractable and highly active relapsing multiple sclerosis - role of alemtuzumab.Neuropsychiatric disease and treatment · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.